Table 1.
Anti-surface marker of CSC CAR
| Antigen | Cancer type | Receptor type* | In vivo | Cancer types** | Reference |
|---|---|---|---|---|---|
| CD44 | Head and neck cancer, lung cancer, gastric cancer, pancreatic cancer, colon cancer, ovarian cancer | ||||
| (CD44v6) | Pancreatic carcinoma | ScFv-CD3ζ | + | 89 | |
| (CD44v7/8) | Cervical carcinoma | ScFv-CD8-CD3ζ | + | 45 | |
| EpCAM | Prostate cancer | ScFv-CD28-CD3ζ | + | Colon cancer, prostate cancer, ovarian cancer, pancreatic cancer, lung cancer, breast cancer, gastric cancer | 4 |
| Peritoneal carcinomatosis | ScFv-CD8-CD28-41BB-CD3ζ | + | 88 | ||
| CD133 | Ovarian cancer | ScFv-CD28-41BB-CD3ζ | − | Glioblastoma, colorectal cancer, breast cancer, neck and head cancer, liver cancer, ovarian cancer | 8 |
| Glioblastoma | ScFv-CD8-CD28-4188-CD3ζ | + | 5 | ||
| Cholangiocarcinoma | ScFv-41BB-CD3ζ | + | 7 | ||
| 5T4 | Nasopharyngeal carcinoma | ScFv-CD8-CD28-CD3ζ | − | Nasopharyngeal carcinoma | 6 |
Notes:
*
Receptor type means the gene construction of the CAR design.
**
Cancer type means the types of malignancies that the surface marker can identify cancer stem cells in.
Abbreviations: CAR, chimeric antigen receptor; CSC, cancer stem cell.